The Nanosonics (ASX: NAN) AGM reveals challenging conditions for the hospital industry but management is buoyed by CORIS progress.

Alcidion (ASX: ALC) is raising capital due delays in NHS procurement.

The Mader (ASX: MAD) update for Q1 FY2024 showed strong momentum however at current share price levels, is it a sound investment?

The Adore Beauty (ASX: ABY) trading update for Q1 FY2024 shows promise but is it capable of becoming more than a mediocre business in the long run?

DUG Technology (ASX: DUG) posted strong results in Q1 FY2024, but is this down to the business or external factors?

The Energy One share price fell during the week after the board walked away from STG’s completely inadequate revised offer.

3 ASX retail stocks reveal falling sales in their trading updates for Q1 FY 2024 but investors should keep an eye on one retailer.

Playside Studios (ASX: PLY) reports record quarterly revenue with growth from the higher margin Original IP division driving the growth.

Ansarada (ASX: AND) is a genuine software business, but the challenge is that demand is potentially quite cyclical.

Spacetalk (ASX: SPA) delivered strong revenue growth in Q1 FY 2024 but investors should pay closer attention to its financial health.

RPM Global (ASX: RUL) will institute investor presentations after their results, including allowing shareholders to ask questions.

Cettire (ASX: CTT) reported rapid growth in quarterly sales in Q1 FY 2024 but questions remain over scalability.

Dropsuite (ASX: DSE) reported record quarterly operating cashflow in Q3 FY 2024 and remains on a path to profitable growth.

Both RPM Global (ASX: RUL) and SRG Global (ASX: SRG) are reporting strong demand from their mining clients.

Xtek (ASX: XTE) released announcements during the week, including a plan to change its name to Highcom (ASX: HCL).

Austco Healthcare (ASX: AHC) shares are up around 50% in the last 6 months. But is the investment thesis on track?

Forager (ASX: FOR) has just announced longer term plans that would allow investors to exit much closer to net asset value…

Prophesying is never easy.

Each of these companies have interesting prospects and saw their share price spike on FY 2023 results.

Here’s why the massive de-rate of the multiple on speculation about weight loss drugs reeks of panic.